N-{4-[2-(4-fluoro-3-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl}-2-naphthamide | 896739-26-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-{4-[2-(4-fluoro-3-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl}-2-naphthamide
• 英文别名: N-[4-[2-(4-fluoro-3-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]pyridin-2-yl]naphthalene-2-carboxamide
• CAS: 896739-26-7
• 化学式: C₂₉H₂₀FN₅O
• 分子量: 473.509
• InChiKey: XHPVGYUXBNJDNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.03
• 拓扑面积：
  72.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor
  申请人：Thompson Toby

  公开号：US20080146612A1

  公开（公告）日：2008-06-19

  The invention provides compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein Ar 1 represents a group (II), (III), (IV) or (V), and A, Ar 2 , n, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.

  该发明提供了公式（I）的化合物或其药学上可接受的盐，其中Ar1代表（II），（III），（IV）或（V）中的一个基团，而A，Ar2，n，R1，R2，R3，R4和R5如说明书中所定义；其制备过程；包含它们的制药组合物；以及它们在治疗中的应用。
• Condensed Imidazole Compound And Use Thereof
  申请人：Uchikawa Osamu

  公开号：US20080167314A1

  公开（公告）日：2008-07-10

  The present invention relates to a compound represented by the formula [I] wherein X 1 , X 2 and X 3 are each an optionally substituted CH or a nitrogen atom, and any one of X 1 , X 2 and X 3 is a nitrogen atom, X 4 is an optionally substituted CH, R 1 is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R 2 is an optionally substituted pyridin-4-yl group, an optionally substituted pyridine-N-oxide-4-yl group or an optionally substituted pyrimidin-4-yl group, or a salt thereof. The compound has superior p38 MAP kinase inhibitory activity and MMP-13 production inhibitory activity, and is useful as an agent for the prophylaxis or treatment and the like of an inflammatory disease, an autoimmune disease, a debilitating disease, an osteoarticular degenerative disease, a neurodegenerative disease, a vascular disease, a neoplastic disease or an infectious disease.

  本发明涉及一种化合物，其表示为式[I]，其中X1、X2和X3分别是可选取代的CH或氮原子，且X1、X2和X3中的任意一个是氮原子，X4是可选取代的CH，R1是可选取代的苯基或可选取代的杂环基，R2是可选取代的吡啶-4-基、可选取代的吡啶-N-氧化物-4-基或可选取代的嘧啶-4-基，或其盐。该化合物具有优异的p38 MAP激酶抑制活性和MMP-13产生抑制活性，可用作预防或治疗炎症性疾病、自身免疫疾病、虚弱性疾病、骨关节退行性疾病、神经退行性疾病、血管疾病、肿瘤性疾病或感染性疾病的药物等。
• CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1832588A1

  公开（公告）日：2007-09-12

  The present invention relates to a compound represented by the formula [I] wherein X1, X2 and X3 are each an optionally substituted CH or a nitrogen atom, and any one of X1, X2 and X3 is a nitrogen atom, X4 is an optionally substituted CH, R1 is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R2 is an optionally substituted pyridin-4-yl group, an optionally substituted pyridine-N-oxide-4-yl group or an optionally substituted pyrimidin-4-yl group, or a salt thereof. The compound has superior p38 MAP kinase inhibitory activity and MMP-13 production inhibitory activity, and is useful as an agent for the prophylaxis or treatment and the like of an inflammatory disease, an autoimmune disease, a debilitating disease, an osteoarticular degenerative disease, a neurodegenerative disease, a vascular disease, a neoplastic disease or an infectious disease.

  本发明涉及一种由式 [I] 表示的化合物 其中X1、X2和X3各自为任选取代的CH或氮原子，且X1、X2和X3中的任一个为氮原子，X4为任选取代的CH，R1为任选取代的苯基或任选取代的杂环基团，R2为任选取代的吡啶-4-基团、任选取代的吡啶-N-氧化-4-基团或任选取代的嘧啶-4-基团，或其盐。该化合物具有优异的 p38 MAP 激酶抑制活性和 MMP-13 生成抑制活性，可用于预防或治疗炎症性疾病、自身免疫性疾病、衰弱性疾病、骨关节退行性疾病、神经退行性疾病、血管性疾病、肿瘤性疾病或传染性疾病等。
• NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR
  申请人：AstraZeneca AB

  公开号：EP1844003A1

  公开（公告）日：2007-10-17
• [EN] NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR<br/>[FR] NOUVEAUX COMPOSES BIAROMATIQUES, INHIBITEURS DU RECEPTEUR P2X7
  申请人：ASTRAZENECA AB

  公开号：WO2006080884A1

  公开（公告）日：2006-08-03

  [EN] The invention provides compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein Ar¹ represents a group (II), (III), (IV) or (V), and A, Ar², n, R¹, R², R³, R⁴ and R⁵ are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.
  [FR] L'invention concerne des composés de formule (I), ou un sel pharmaceutiquement acceptable de ceux-ci, dans laquelle Ar¹ représente un groupe (II), (III), (IV) ou (V), et A, Ar², n, R¹, R², R³, R⁴ et R⁵ sont tels que définis dans la description. L'invention concerne également un procédé de préparation de ces composés, des compositions pharmaceutiques les contenant, ainsi que leur utilisation thérapeutique.